Skip to main content

Table 4 Clinical profiles of patients with SSc in the presence or absence of gAChR Abs

From: Detecting gastrointestinal manifestations in patients with systemic sclerosis using anti-gAChR antibodies

CharacteristicsSSc with gAChR Abs (n = 7)SSc without gAChR Abs (n = 43)p value
Age (years)62.9 ± 14.062.1 ± 9.00.764
Age at onset (years)57.1 ± 12.554.8 ± 12.40.646
Disease duration (years)5.7 ± 5.67.3 ± 8.70.911
Sex, female (%)6 (85.7)38 (88.4)1.000
Diffuse SSc (%)4 (57.1)13 (30.2)0.451
Raynaud’s phenomenon (%)7 (100.0)43 (100.0)1.000
Digital ulcers (%)2 (28.6)7 (16.3)0.615
Renal crisis (%)1 (14.3)1 (2.3)0.287
Interstitial pneumonitis (%)4 (57.1)16 (37.2)0.717
Pulmonary hypertension (%)1 (14.3)2 (4.7)0.394
GI manifestations
 GERD (%)3 (42.9)11 (25.6)0.677
 Paralytic ileus (%)1 (14.3)1 (2.3)0.287
 Constipation (%)2 (28.6)8 (18.6)0.637
 Diarrhea (%)1 (14.3)0 (0.0)0.157
Other Abs
 ACA (+) (%)3 (42.9)22 (51.2)1.000
 Anti-Scl70 Abs (+) (%)2 (28.6)10 (23.3)1.000
 Other Abs (+) (%)1 (14.3)4 (9.3)0.559
 Negative (%)1 (14.3)7 (16.3)1.000
Other laboratory data
 IgG (mg/dL)1775.0 ± 614.21548.8 ± 363.60.459
 KL-6 (U/mL)666.0 ± 678.3572.6 ± 642.40.534
 NT-proBNP (pg/mL)114.1 ± 128.9217.4 ± 418.60.530
 %FVC109.8 ± 25.598.8 ± 22.30.311
 FEV1.0%78.5 ± 13.679.9 ± 10.00.786
 %DLCO61.9 ± 23.871.7 ± 17.50.262
 DLCO/VA70.5 ± 15.685.7 ± 17.20.068
 TR-PG28.4 ± 17.124.0 ± 7.90.953
 Estimated PA systolic pressure26.5 ± 8.529.3 ± 8.40.528
 EF71.6 ± 3.470.8 ± 6.70.800
Serum biomarkers
 VEGF (pg/mL)441.6 ± 112.1480.2 ± 476.50.631
 PIGF (pg/mL)16.6 ± 6.614.8 ± 8.60.482
 GDF-15 (pg/mL)1595.9 ± 1529.01423.1 ± 1086.50.941
 PTX3 (ng/mL)2.3 ± 1.23.1 ± 1.50.336
 Endostatin (ng/mL)101.8 ± 21.483.3 ± 18.70.046*
 TGFβ113,038.6 ± 12,382.613,334.3 ± 7692.20.506
Immunotherapies
 Oral PSL (%)1 (14.3)6 (14.0)1.000
 Immunosuppressants (%)1 (14.3)3 (7.0)0.532
 Steroid pulse therapy (%)0 (0.0)0 (0.0)1.000
 IVIg (%)0 (0.0)0 (0.0)1.000
 Plasmapheresis (%)0 (0.0)0 (0.0)1.000
  1. *p < 0.05 was considered statistically significant
  2. Abbreviations: Abs autoantibodies, ACA anti-centromere antibodies, DLCO diffusing capacity of lung for carbon monoxide, EF ejection fraction, FEV forced expiratory volume, FVC forced vital capacity, gAChR ganglionic acetylcholine receptor, GDF-15 growth differentiation factor-15, GERD gastroesophageal reflux disease, GI gastrointestinal, PA pulmonary artery, PIGF placenta growth factor, PTX3 pentraxin 3, SSc systemic sclerosis, TGFβ1 transforming growth factor β1, TR-PG tricuspid regurgitation pressure gradient, VEGF vascular endothelial growth factor